Aldosterone blockade in post-acute myocardial infarction heart failure

Bertram Pitt*, Roberto Ferrari, Mihai Gheorghiade, Dirk J. Van Veldhuisen, Henry Krum, John McMurray, Jose Lopez-Sendon

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Development of heart failure (HF) or left ventricular systolic dysfunction (LVSD) significantly increases mortality post acute myocardial infarction (AMI). Aldosterone contributes to the development and progression of HF post AMI, and major guidelines now recommend aldosterone blockade in this setting. However, lack of practical experience with aldosterone blockade may make clinicians hesitant to use these therapies. This review is based on a consensus cardiology conference that occurred in May 2005 (New York City) concerning these topics. Potential barriers to the use of aldosterone blockade are discussed and an algorithm for appropriate in-hospital pharmacologic management of AMI with LVSD and/or HF is presented.

Original languageEnglish (US)
Pages (from-to)434-438
Number of pages5
JournalClinical Cardiology
Issue number10
StatePublished - Oct 2006


  • Aldosterone
  • Eplerenone
  • Heart failure
  • Left ventricular systolic dysfunction
  • Myocardial infarction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Aldosterone blockade in post-acute myocardial infarction heart failure'. Together they form a unique fingerprint.

Cite this